McKesson Corporation (MCK)
NYSE: MCK · Real-Time Price · USD
920.35
-21.54 (-2.29%)
At close: Mar 18, 2026, 4:00 PM EDT
918.00
-2.35 (-0.26%)
After-hours: Mar 18, 2026, 7:48 PM EDT
Revenue
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
|---|
| Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 | Mar '20 Mar 31, 2020 |
|---|
North American Pharmaceutical Revenue | 88.32B | | | | | | | | | | | | | | | | | | | | | | | |
North American Pharmaceutical Revenue Growth | 8.77% | | | | | | | | | | | | | | | | | | | | | | | |
Oncology & Multispecialty Revenue | 13.01B | | | | | | | | | | | | | | | | | | | | | | | |
Oncology & Multispecialty Revenue Growth | 37.05% | | | | | | | | | | | | | | | | | | | | | | | |
Prescription Technology Solutions Revenue | 1.50B | | | | | | | | | | | | | | | | | | | | | | | |
Prescription Technology Solutions Revenue Growth | 9.41% | | | | | | | | | | | | | | | | | | | | | | | |
Medical Surgical Solutions Revenue | 2.99B | | | | | | | | | | | | | | | | | | | | | | | |
Medical Surgical Solutions Revenue Growth | 1.42% | | | | | | | | | | | | | | | | | | | | | | | |
| 335.00M | | | | | | | | | | | | | | | | | | | | | | | |
Other Segment Revenue Growth | 18.38% | | | | | | | | | | | | | | | | | | | | | | | |
| - | | | | | | | | | | | | | | | | | | | | | | | |
| 106.16B | | | | | | | | | | | | | | | | | | | | | | | |
| 11.40% | | | | | | | | | | | | | | | | | | | | | | | |
EBIT
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
|---|
| Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 | Mar '20 Mar 31, 2020 |
|---|
North American Pharmaceutical Operating Profit | 1.06B | | | | | | | | | | | | | | | | | | | | | | | |
North American Pharmaceutical Operating Profit Growth | 41.80% | | | | | | | | | | | | | | | | | | | | | | | |
Oncology & Multispecialty Operating Profit | 304.00M | | | | | | | | | | | | | | | | | | | | | | | |
Oncology & Multispecialty Operating Profit Growth | 50.50% | | | | | | | | | | | | | | | | | | | | | | | |
Prescription Technology Solutions Operating Profit | 261.00M | | | | | | | | | | | | | | | | | | | | | | | |
Prescription Technology Solutions Operating Profit Growth | 19.18% | | | | | | | | | | | | | | | | | | | | | | | |
Medical Surgical Solutions Operating Profit | 265.00M | | | | | | | | | | | | | | | | | | | | | | | |
Medical Surgical Solutions Operating Profit Growth | -1.49% | | | | | | | | | | | | | | | | | | | | | | | |
Other Segment Operating Profit | 31.00M | | | | | | | | | | | | | | | | | | | | | | | |
Other Segment Operating Profit Growth | 121.43% | | | | | | | | | | | | | | | | | | | | | | | |
| -297.00M | | | | | | | | | | | | | | | | | | | | | | | |
| 1.62B | | | | | | | | | | | | | | | | | | | | | | | |
Operating Income (Total) Growth | 32.27% | | | | | | | | | | | | | | | | | | | | | | | |
Updated Feb 4, 2026. Data Source:
Fiscal.ai.
